Stock Analiz

Arrowhead Pharmaceuticals, Inc. (ARWR) financials: revenue, earnings and cash flow

Fiscal 2017–2026 · from SEC filings · data as of November 13, 2026

Summary

Arrowhead Pharmaceuticals’s revenue went from $31M in fiscal 2017 to $451M in fiscal 2026, growth of about 34.4% a year.

Net income in fiscal 2026 was -$724M, a net margin of -160.6%; the best year in this period was 2019 with $68M.

Free cash flow was -$284M in fiscal 2026 and positive in 3 of the 10 years shown.

The diluted share count rose 92% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $31M172018: $16M182019: $169M192020: $88M202021: $138M212022: $243M222023: $241M232024: $4M242025: $829M252026: $451M26$451M
Net income
2017: -$34M172018: -$54M182019: $68M192020: -$85M202021: -$141M212022: -$176M222023: -$205M232024: -$599M242025: -$2M252026: -$724M26-$724M
Free cash flow
2017: -$32M172018: -$49M182019: $161M192020: -$108M202021: $148M212022: -$189M222023: -$331M232024: -$604M242025: $157M252026: -$284M26-$284M
EPS (diluted)
2017: $-0.47172018: $-0.65182019: $0.69192020: $-0.84202021: $-1.36212022: $-1.67222023: $-1.92232024: $-5.00242025: $-0.01252026: $-5.1126$-5.11

Income statement

Fiscal year2026202520242023202220212020201920182017
Revenue$451M$829M$4M$241M$243M$138M$88M$169M$16M$31M
Gross profit——————————
Operating income-$707M$98M-$601M-$205M-$179M-$149M-$93M$61M-$56M-$37M
Net income-$724M-$2M-$599M-$205M-$176M-$141M-$85M$68M-$54M-$34M
EPS (diluted)$-5.11$-0.01$-5.00$-1.92$-1.67$-1.36$-0.84$0.69$-0.65$-0.47
R&D$739M$607M$506M$353M$297M$206M$129M$81M$53M$51M
Revenue growth−45.6%+23258.2%−98.5%−1.0%+75.9%+57.2%−47.9%+945.7%−48.6%+19736.5%

Cash flow

Fiscal year2026202520242023202220212020201920182017
Operating cash flow-$272M$180M-$463M-$154M-$136M$171M-$96M$173M-$47M-$24M
Capital spending-$12M-$23M-$141M-$177M-$53M-$24M-$12M-$12M-$1M-$8M
Free cash flow-$284M$157M-$604M-$331M-$189M$148M-$108M$161M-$49M-$32M
Dividends paid$0$0$0$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay$68M$63M$74M$78M$121M$77M$43M$12M$8M$8M

Balance sheet

Fiscal year2026202520242023202220212020201920182017
Cash$1.2B$919M$681M$404M$108M$311M$229M$259M$77M$66M
Debt$845M$151M$511M$115M$82M$26M$21M—$2M$3M
Equity$50M$466M$185M$271M$399M$409M$462M$245M$96M$81M
Total assets$1.7B$1.4B$1.1B$766M$692M$710M$523M$350M$112M$104M
Shares (diluted)142M134M120M107M105M104M101M99M84M74M

Margins and returns

Fiscal year2026202520242023202220212020201920182017
Gross margin——————————
Operating margin-156.9%11.9%-16927.1%-85.2%-73.4%-107.8%-105.9%36.2%-346.5%-117.8%
Net margin-160.6%-0.2%-16882.4%-85.3%-72.4%-101.8%-96.1%40.3%-337.3%-109.5%
FCF margin-63.0%18.9%-17018.3%-137.3%-77.7%106.8%-122.5%95.4%-301.4%-101.4%
ROIC-78.3%9.3%-86.0%-41.9%-29.4%-27.1%-15.2%24.9%-45.0%-34.8%
ROE-1439.4%-0.4%-323.3%-75.6%-44.2%-34.4%-18.3%27.8%-56.8%-42.2%

Frequently asked questions

What is Arrowhead Pharmaceuticals’s annual revenue?

$451M in fiscal 2026.

How much profit does Arrowhead Pharmaceuticals make?

Net income was -$724M in fiscal 2026 (net margin -160.6%).

Is Arrowhead Pharmaceuticals’s revenue growing?

No: revenue fell 45.6% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.